AC Immune SA has a consensus price target of $13, established from looking at the 9 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on March 15, 2024, November 13, 2023, and August 7, 2023. With an average price target of $16 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 577.97% upside for AC Immune SA from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/15/2024 | ACIU | Buy Now | AC Immune | $2.36 | 577.97% | HC Wainwright & Co. | Andrew Fein | → $16 | Reiterates | Buy → Buy | Get Alert |
11/13/2023 | ACIU | Buy Now | AC Immune | $2.36 | 577.97% | HC Wainwright & Co. | Andrew Fein | → $16 | Reiterates | Buy → Buy | Get Alert |
08/07/2023 | ACIU | Buy Now | AC Immune | $2.36 | 577.97% | HC Wainwright & Co. | Andrew Fein | → $16 | Reiterates | Buy → Buy | Get Alert |
06/28/2023 | ACIU | Buy Now | AC Immune | $2.36 | 577.97% | HC Wainwright & Co. | Andrew Fein | → $16 | Reiterates | Buy → Buy | Get Alert |
05/01/2023 | ACIU | Buy Now | AC Immune | $2.36 | 577.97% | HC Wainwright & Co. | Andrew Fein | → $16 | Reiterates | → Buy | Get Alert |
04/19/2023 | ACIU | Buy Now | AC Immune | $2.36 | 577.97% | HC Wainwright & Co. | Andrew Fein | → $16 | Reiterates | → Buy | Get Alert |
03/17/2023 | ACIU | Buy Now | AC Immune | $2.36 | 577.97% | HC Wainwright & Co. | Andrew Fein | → $16 | Reiterates | → Buy | Get Alert |
07/11/2022 | ACIU | Buy Now | AC Immune | $2.36 | 323.73% | SVB Leerink | Marc Goodman | $15 → $10 | Maintains | Outperform | Get Alert |
12/20/2021 | ACIU | Buy Now | AC Immune | $2.36 | 535.59% | SVB Leerink | Marc Goodman | — | Maintains | Outperform | Get Alert |
The latest price target for AC Immune (NASDAQ: ACIU) was reported by HC Wainwright & Co. on March 15, 2024. The analyst firm set a price target for $16.00 expecting ACIU to rise to within 12 months (a possible 577.97% upside). 5 analyst firms have reported ratings in the last year.
The latest analyst rating for AC Immune (NASDAQ: ACIU) was provided by HC Wainwright & Co., and AC Immune reiterated their buy rating.
There is no last upgrade for AC Immune.
There is no last downgrade for AC Immune.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AC Immune, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AC Immune was filed on March 15, 2024 so you should expect the next rating to be made available sometime around March 15, 2025.
While ratings are subjective and will change, the latest AC Immune (ACIU) rating was a reiterated with a price target of $0.00 to $16.00. The current price AC Immune (ACIU) is trading at is $2.36, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.